Adaptive Biotechnologies Corporation (ADPT) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”...

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages...

Form 4 - Statement of changes in beneficial ownership of securities

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial...

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

SEATTLE, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report